Scientists have made significant advances in treating Alzheimer’s, with monoclonal antibodies emerging as a major stride to stop progression and address symptoms. Alzheimer’s disease is caused by the ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day’s high of $1.11 ...

Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administrationPhase 1/2 clinical data for VYD2311 to date are positiv ...

These drugs can also be taken orally. Other cancer therapies, such as immunotherapies and targeted therapies, use monoclonal antibodies. Infusion therapy is majorly required for administering ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody treatment shown to slow cognitive decline in ...

With an increasing understanding of the underlying pathogenetic mechanisms and identification of specific therapeutic targets, monoclonal antibody treatment has been an ideal strategy for inducing ...

Rituximab, a monoclonal antibody directed against the CD20 molecule ... which potentially accounts for some infusion-related adverse effects. No evidence for alteration in B cell cytokine profiles ...